{"prompt": "['Novartis', 'Confidential', 'Page 48', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Adverse events must be recorded under the signs, symptoms or diagnosis associated with them,', 'accompanied by the following information (as far as possible) (if the event is serious refer to', 'Section 10.1.2):', '1. the severity grade', 'mild: usually transient in nature and generally not interfering with normal activities', 'moderate: sufficiently discomforting to interfere with normal activities', 'severe: prevents normal activities', '2.', 'its relationship to the study treatment. If the event is due to lack of efficacy or progression', 'of underlying illness (i.e. progression of the study indication) the assessment of causality', 'will usually be \"not suspected\\' The rationale for this guidance is that the symptoms of a', 'lack of efficacy or progression of underlying illness are not caused by the trial drug, they', 'happen in spite of its administration and/or both lack of efficacy and progression of', 'underlying disease can only be evaluated meaningfully by an analysis of cohorts, not on a', 'single subject.', '3. its duration (start and end dates) or if the event is ongoing, an outcome of not', 'recovered/not resolved must be reported.', '4. whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which', 'seriousness criteria have been met', '5. action taken regarding with study treatment', '6. its outcome i.e., its recovery status or whether it was fatal', 'All adverse events must be treated appropriately. Treatment may include one or more of the', 'following:', 'Dose not changed', 'Dose Reduced/increased', 'Drug interrupted/withdrawn', 'Conditions that were already present at the time of informed consent should be recorded in', 'medical history of the subject.', 'Adverse events (including lab abnormalities that constitute AEs) should be described using a', 'diagnosis whenever possible, rather than individual underlying signs and symptoms.', 'Adverse event monitoring should be continued for at least 14 days (or 5 half-lives or end of', 'study visit, whichever is longer) following the last dose of study treatment', 'Information about adverse drug reactions for the investigational drug can be found in the', 'Investigator Brochure (IB).', 'Abnormal laboratory values or test results constitute adverse events only if they fulfill at least', 'one of the following criteria:', 'they induce clinical signs or symptoms', 'they are considered clinically significant', 'they require therapy', 'Clinically significant abnormal laboratory values or test results must be identified through a', 'review of values outside of normal ranges/clinically notable ranges, significant changes from']['Novartis', 'Confidential', 'Page 49', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'baseline or the previous visit, or values which are considered to be non-typical in subjects with', 'the underlying disease. Alert ranges for laboratory and other test abnormalities are included in', 'Section 16.1.', '10.1.2', 'Serious adverse events', 'An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)]', 'undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following', 'criteria:', 'fatal', 'life-threatening', 'Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of', 'death at the time of the reaction; it does not refer to a reaction that hypothetically might have', 'caused death if it were more severe (please refer to the ICH-E2D Guidelines).', 'results in persistent or significant disability/incapacity', 'constitutes a congenital anomaly/birth defect', 'requires inpatient hospitalization or prolongation of existing hospitalization, unless', 'hospitalization is for:', '1. routine treatment or monitoring of the studied indication, not associated with any', 'deterioration in condition under study', '2. elective or pre-planned treatment for a pre-existing condition that is unrelated to the', 'indication under study and has not worsened since signing the informed consent', \"3. social reasons and respite care in the absence of any deterioration in the subject's general\", 'condition', '4. treatment on an emergency outpatient basis for an event not fulfilling any of the', 'definitions of a SAE given above and not resulting in hospital admission', 'is medically significant, e.g. defined as an event that jeopardizes the subject or may', 'require medical or surgical intervention to prevent one of the outcomes listed above', 'Medical and scientific judgment should be exercised in deciding whether other situations should', 'be considered serious reactions, such as important medical events that might not be immediately', 'life-threatening or result in death or hospitalization but might jeopardize the subject or might', 'require intervention to prevent one of the other outcomes listed above. Such events should be', 'considered as \"medically significant\". Examples of such events are intensive treatment in an', 'emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do', 'not result in hospitalization or development of dependency or abuse (please refer to the ICH-', 'E2D Guidelines).', 'All malignant neoplasms will be assessed as serious under \"medically significant\" if other', 'seriousness criteria are not met.', 'Any suspected transmission via a medicinal product of an infectious agent is also considered a', 'serious adverse reaction.', 'All reports of intentional misuse and abuse of the product are also considered serious adverse', 'event irrespective if a clinical event has occurred.']\n\n###\n\n", "completion": "END"}